Pharmaceutical companies are investing in shifting their operations to a few bioscience hotspots, even at a time of cutbacks, says this Wall Street Journal article. While cities like Boston and San Francisco are being helped by companies' relocations and the construction it entails, the suburban areas being left like New Jersey and Connecticut are not doing as well.